Jing Huang
Affiliations: | Beijing Normal University, Beijing, Beijing Shi, China |
Area:
attentionGoogle:
"Jing Huang"Mean distance: 53433
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Zhang B, Song Y, Luo S, et al. (2023) Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. Cell Reports. Medicine. 101301 |
Yuan X, Li D, Hu Y, et al. (2023) Neural and behavioral evidence supporting the relationship between habitual exercise and working memory precision in healthy young adults. Frontiers in Neuroscience. 17: 1146465 |
Xin D, Song Y, Mu L, et al. (2023) The efficacy and safety of nanoparticle albumin bound-paclitaxel-based regimen as second- or third-line treatment in patients with advanced esophageal squamous cell carcinoma. Thoracic Cancer |
Zhao C, Kong Y, Li D, et al. (2023) Suppression of distracting inputs by visual-spatial cues is driven by anticipatory alpha activity. Plos Biology. 21: e3002014 |
Song Y, Zhang B, Xin D, et al. (2023) First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. Nature Medicine |
Li D, Hu Y, Qi M, et al. (2023) Prioritizing flexible working memory representations through retrospective attentional strengthening. Neuroimage. 269: 119902 |
Mu L, Song Y, Zhao K, et al. (2021) SHR-1316, an anti-PD-L1 antibody, plus chemotherapy as the first-line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study. Thoracic Cancer |
Song Y, Xiao J, Fang W, et al. (2021) The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma. Cancer Biology & Medicine |
Huang J, Xiao J, Fang W, et al. (2021) Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial. Cancer Medicine |
Song Y, Li N, Li Q, et al. (2020) HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial. Journal For Immunotherapy of Cancer. 8 |